CytoMed Therapeutics Limited Ordinary Shares (GDTC) — Long-term Investment Intensity
CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a Long-term Investment Intensity of 0.2% as of December 2025. Long-term investments of $18.21K represent 0.2% of total assets of $7.98 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Explore GDTC cash generation efficiency to assess how effectively this company generates cash.
LT Investment Intensity
Long-term Investments
Total Assets
Country
CytoMed Therapeutics Limited Ordinary Shares Long-term Investment Intensity (2021–2025)
This chart shows how CytoMed Therapeutics Limited Ordinary Shares's Long-term Investment Intensity has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the intensity stands at 0.2%, reflecting long-term investments of $18.21K against total assets of $7.98 Million USD. Explore CytoMed Therapeutics Limited Ordinary Sh (GDTC) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for CytoMed Therapeutics Limited Ordinary Shares (2021–2025)
The table below presents the year-by-year Long-term Investment Intensity for CytoMed Therapeutics Limited Ordinary Shares from 2021 to 2025, covering 5 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see GDTC stock market capitalisation.
| Year | LT Investment Intensity | LT Investments (USD) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 0.2% | $18.21K | $7.98 Million | ▼ -2.0 pp |
| 2024 | 2.2% | $220.95K | $10.07 Million | ▲ +0.6 pp |
| 2023 | 1.6% | $195.07K | $12.40 Million | ▼ -3.0 pp |
| 2022 | 4.6% | $239.42K | $5.25 Million | ▲ +0.1 pp |
| 2021 | 4.5% | $272.97K | $6.10 Million | — |